Evidence map›Paper›PMID 37339172›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.

Karolin Heinze, Evan S Cairns, Shelby Thornton, Bronwyn Harris, Katy Milne, Marcel Grube, Charlotte Meyer, Anthony N Karnezis, Sian Fereday, Dale W Garsed and 18 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 13 institutions in 4 countries.

Karolin HeinzeDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-5066-3780
Evan S CairnsDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.ORCID 0000-0002-5719-8965
Shelby ThorntonOVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-0094-4779
Bronwyn HarrisMolecular and Cellular Immunology Core (MCIC), Deeley Research Centre, BC Cancer, Victoria, Canada.ORCID 0000-0003-4104-7908
Katy MilneMolecular and Cellular Immunology Core (MCIC), Deeley Research Centre, BC Cancer, Victoria, Canada.ORCID 0000-0001-5616-1821
Marcel GrubeDepartment of Women's Health, Tübingen University Hospital, Tübingen, Germany.ORCID 0000-0002-6609-8827
Charlotte MeyerOVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0009-0003-9863-3489
Anthony N KarnezisDepartment of Pathology and Laboratory, UC Davis Medical Center, Sacramento, California.ORCID 0000-0003-2924-1126
Sian FeredayPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-8559-8579
Dale W GarsedPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0003-1223-0121
Samuel C Y LeungOVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-0138-7254
Derek S ChiuOVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-7591-4881
Malak MoubarakKliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany.ORCID 0000-0003-1782-2089
Philipp HarterKliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany.ORCID 0000-0002-9663-5005
Florian HeitzKliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany.ORCID 0000-0002-2412-0352
Jessica N McAlpineDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.ORCID 0000-0001-6003-485X
Anna DeFazioCentre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0003-0057-4744
David D L BowtellPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0001-9089-7525
Ellen L GoodeMayo Clinic, Department of Health Science Research, Division of Epidemiology, Rochester, Minnesota.ORCID 0000-0002-9094-8326
Malcolm PikeDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4891-1199
Susan J RamusSchool of Clinical Medicine, UNSW Medicine and Health, University of New South Wales Sydney, Sydney, Australia.ORCID 0000-0003-0005-7798
C Leigh PearceMultidisciplinary Ovarian Cancer Outcomes Group (Consortium).ORCID 0000-0002-8023-7846
Annette StaeblerInstitute of Pathology, University Hospital of Tübingen, Tübingen, Germany.ORCID 0000-0003-0103-6059
Martin KöbelDepartment of Pathology, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-6615-2037
Stefan KommossDepartment of Women's Health, Tübingen University Hospital, Tübingen, Germany.ORCID 0000-0003-0534-1501
Aline TalhoukDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.ORCID 0000-0001-7760-410X
Brad H NelsonOVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-4445-5539
Michael S AnglesioDepartment of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.ORCID 0000-0003-1639-5003
University of British Columbia · CAVancouver General Hospital · CAOutcomes Research Consortium · USPeter MacCallum Cancer Centre · AUUniversity Children's Hospital Tübingen · DEKliniken Essen-Mitte · DEOccupational Cancer Research Centre · CAHumboldt-Universität zu Berlin · DEMayo Clinic in Florida · USMemorial Sloan Kettering Cancer Center · USThe University of Sydney · AUUniversity of Calgary · CAUniversity of California Davis Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0M
Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and RiskR01CA248288 · NCI · MAYO CLINIC ROCHESTER · PI Stacey J Winham · 2021 to 2026
$4.8M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA248288
6 · The paper itself

Abstract

purposeEndometrioid ovarian carcinoma (ENOC) is the second most-common type of ovarian carcinoma, comprising 10%-20% of cases. Recently, the study of ENOC has benefitted from comparisons to endometrial carcinomas including defining ENOC with four prognostic molecular subtypes. Each subtype suggests differential mechanisms of progression, although tumor-initiating events remain elusive. There is evidence that the ovarian microenvironment may be critical to early lesion establishment and progression. However, while immune infiltrates have been well studied in high-grade serous ovarian carcinoma, studies in ENOC are limited. EXPERIMENTAL

designWe report on 210 ENOC, with clinical follow-up and molecular subtype annotation. Using multiplex IHC and immunofluorescence, we examine the prevalence of T-cell lineage, B-cell lineage, macrophages, and populations with programmed cell death protein 1 or programmed death-ligand 1 across subtypes of ENOC.

resultsImmune cell infiltrates in tumor epithelium and stroma showed higher densities in ENOC subtypes with known high mutation burden (POLEmut and MMRd). While molecular subtypes were prognostically significant, immune infiltrates were not (overall survival P > 0.2). Analysis by molecular subtype revealed that immune cell density was prognostically significant in only the no specific molecular profile (NSMP) subtype, where immune infiltrates lacking B cells (TILB minus) had inferior outcome (disease-specific survival: HR, 4.0; 95% confidence interval, 1.1-14.7; P < 0.05). Similar to endometrial carcinomas, molecular subtype stratification was generally superior to immune response in predicting outcomes.

conclusionsSubtype stratification is critical for better understanding of ENOC, in particular the distribution and prognostic significance of immune cell infiltrates. The role of B cells in the immune response within NSMP tumors warrants further study.

Indexed as

Carcinoma, EndometrioidEndometrial NeoplasmsOvarian NeoplasmsBiomarkers, TumorCarcinoma, Ovarian EpithelialFemaleHumansPrognosisTumor MicroenvironmentBiomarkers, Tumor

Identifiers

PMID37339172
PMCPMC10472107
OpenAlexW4381434619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.